174 related articles for article (PubMed ID: 35619540)
1. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.
Gu X; Zhu Q; Tian G; Song W; Wang T; Wang A; Chen X; Qin S
Cancer Med; 2022 Sep; 11(17):3282-3295. PubMed ID: 35619540
[TBL] [Abstract][Full Text] [Related]
2. SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemotherapeutic agents in vitro.
Zhao F; Huang Y; Zhang Y; Li X; Chen K; Long Y; Li F; Ma X
Mol Biol Rep; 2022 Jul; 49(7):6613-6621. PubMed ID: 35552960
[TBL] [Abstract][Full Text] [Related]
3. Cilia loss sensitizes cells to transformation by activating the mevalonate pathway.
Deng YZ; Cai Z; Shi S; Jiang H; Shang YR; Ma N; Wang JJ; Guan DX; Chen TW; Rong YF; Qian ZY; Zhang EB; Feng D; Zhou QL; Du YN; Liu DP; Huang XX; Liu LM; Chin E; Li DS; Wang XF; Zhang XL; Xie D
J Exp Med; 2018 Jan; 215(1):177-195. PubMed ID: 29237705
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer.
Shi S; Guo D; Ye L; Li T; Fei Q; Lin M; Yu X; Jin K; Wu W
Cell Death Dis; 2023 Nov; 14(11):778. PubMed ID: 38012214
[TBL] [Abstract][Full Text] [Related]
5. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
6. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer.
Oni TE; Biffi G; Baker LA; Hao Y; Tonelli C; Somerville TDD; Deschênes A; Belleau P; Hwang CI; Sánchez-Rivera FJ; Cox H; Brosnan E; Doshi A; Lumia RP; Khaledi K; Park Y; Trotman LC; Lowe SW; Krasnitz A; Vakoc CR; Tuveson DA
J Exp Med; 2020 Sep; 217(9):. PubMed ID: 32633781
[TBL] [Abstract][Full Text] [Related]
7. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation.
Zhou M; Pan S; Qin T; Zhao C; Yin T; Gao Y; Liu Y; Zhang Z; Shi Y; Bai Y; Gong J; Guo X; Wang M; Qin R
J Exp Clin Cancer Res; 2022 Sep; 41(1):288. PubMed ID: 36171592
[TBL] [Abstract][Full Text] [Related]
8. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation.
Xu J; Quan G; Huang W; Jiang J
Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
[TBL] [Abstract][Full Text] [Related]
9. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitinase USP35 stabilizes BRPF1 to activate mevalonate (MVA) metabolism during prostate tumorigenesis.
Lin G; Huang T; Zhang X; Wang G
Cell Death Discov; 2022 Nov; 8(1):453. PubMed ID: 36357379
[TBL] [Abstract][Full Text] [Related]
11. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
[TBL] [Abstract][Full Text] [Related]
12. KIF4A Regulates the Progression of Pancreatic Ductal Adenocarcinoma through Proliferation and Invasion.
Chen J; Zhao CC; Chen FR; Feng GW; Luo F; Jiang T
Biomed Res Int; 2021; 2021():8249293. PubMed ID: 34805404
[TBL] [Abstract][Full Text] [Related]
13. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability.
Pan Q; Zhong S; Wang H; Wang X; Li N; Li Y; Zhang G; Yuan H; Lian Y; Chen Q; Han Y; Guo J; Liu Q; Qiu T; Jiang J; Li Q; Tan M; Yin H; Peng J; Xiao Y; Qin J
Mol Cell; 2021 Jul; 81(13):2736-2751.e8. PubMed ID: 33932349
[TBL] [Abstract][Full Text] [Related]
14. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC.
Li J; Tong H; Li D; Jiang Q; Zhang Y; Tang W; Jin D; Chen S; Qin X; Zhang S; Xue R
Mol Med; 2021 Aug; 27(1):95. PubMed ID: 34470609
[TBL] [Abstract][Full Text] [Related]
16. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
[TBL] [Abstract][Full Text] [Related]
18. The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.
Shen H; Ye F; Xu D; Fang L; Zhang X; Zhu J
Cell Death Dis; 2021 Dec; 13(1):15. PubMed ID: 34930894
[TBL] [Abstract][Full Text] [Related]
19. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer.
Wang Q; Li M; Gan Y; Jiang S; Qiao J; Zhang W; Fan Y; Shen Y; Song Y; Meng Z; Yao M; Gu J; Zhang Z; Tu H
Theranostics; 2020; 10(5):2141-2157. PubMed ID: 32089737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
